Mrs Rachel Howard, Nottingham Primary Care Research Partnership, Broxtowe & Hucknall PCT, Hucknall Health Centre, Nottingham NG8 1HT, UK. Tel: +44(0)115 8590770 Fax: +44(0)115 8590772 E-mail: email@example.com
Previous systematic reviews have found that drug-related morbidity accounts for 4.3% of preventable hospital admissions. None, however, has identified the drugs most commonly responsible for preventable hospital admissions. The aims of this study were to estimate the percentage of preventable drug-related hospital admissions, the most common drug causes of preventable hospital admissions and the most common underlying causes of preventable drug-related admissions.
Bibliographic databases and reference lists from eligible articles and study authors were the sources for data. Seventeen prospective observational studies reporting the proportion of preventable drug-related hospital admissions, causative drugs and/or the underlying causes of hospital admissions were selected. Included studies used multiple reviewers and/or explicit criteria to assess causality and preventability of hospital admissions. Two investigators abstracted data from all included studies using a purpose-made data extraction form.
From 13 papers the median percentage of preventable drug-related admissions to hospital was 3.7% (range 1.4–15.4). From nine papers the majority (51%) of preventable drug-related admissions involved either antiplatelets (16%), diuretics (16%), nonsteroidal anti-inflammatory drugs (11%) or anticoagulants (8%). From five studies the median proportion of preventable drug-related admissions associated with prescribing problems was 30.6% (range 11.1–41.8), with adherence problems 33.3% (range 20.9–41.7) and with monitoring problems 22.2% (range 0–31.3).
Four groups of drugs account for more than 50% of the drug groups associated with preventable drug-related hospital admissions. Concentrating interventions on these drug groups could reduce appreciably the number of preventable drug-related admissions to hospital from primary care.
Drug-related problems are an important cause of morbidity and mortality and a significant burden on healthcare resources [1, 2]. Previous systematic reviews have shown that 4.9–7.7% of admissions are related to adverse drug events [3, 4] and a median of 4.3% of admissions are considered to be drug-related and preventable . These reviews have largely concentrated on the proportion of admissions that are drug related. One review assessed which drugs most commonly contributed to drug-related morbidity, but combined events which had occurred in hospital with those which occurred in a community setting . Little is known about which drugs are most frequently responsible for preventable drug-related hospital admissions, or the most common underlying causes of these admissions.
We undertook a systematic review to address the following questions:
• What proportion of hospital admissions are drug related and preventable?
• What are the most common drug causes of preventable hospital admissions?
• What are the most common underlying causes of preventable drug-related admissions?
We sought to identify both published and unpublished studies using a high-sensitivity, low-specificity search of the following databases: the Cochrane controlled trials register, Cochrane database of systematic reviews, Index UK, US Dissertation abstracts, International Pharmaceutical Abstracts, MEDLINE, EMBASE, Cinahl, Pharmline, National Research Register, Psychinfo, Science Citation Index and SIGLE.
In addition, bibliography lists of published reviews were searched for relevant papers [3–5]. Where possible, corresponding authors were contacted for further information. Details of the search strategy are available from the corresponding author.
Selection and abstraction
Two reviewers (S.S. and S.R.) independently screened titles for relevance, resolving disagreements through discussion. The same reviewers independently reviewed the abstracts of articles considered to be relevant. Full papers were retrieved for detailed analysis and assessed according to the inclusion criteria. Two reviewers (S.S. and R.L.H.) abstracted data from papers meeting these criteria and a third reviewer (A.J.A.) verified the data.
Our inclusion criteria were as follows:
• Types of studies: studies eligible for inclusion prospectively identified patients admitted with preventable drug-related admissions to hospital using medical record review. Studies reported the number and proportion of preventable drug-related admissions and at least one of the following: types of medication associated with preventable drug-related admissions and underlying causes of preventable drug-related admissions.
• Types of participants: patients aged ≥ 16 years.
• Types of admissions: admissions to hospital from primary care judged to be drug related and preventable. Admissions caused by adverse drug reactions, under- or overtreatment and problems with patient adherence to medication were included.
Studies excluded from the review were those that: did not use medical record review to identify admissions; focused on specific diseases or treatments, a single drug-related problem, or admissions to a single specialist unit; focused on admissions attributed to drugs of abuse or intentional overdose; focused on hospital readmissions only; focused on events occurring in hospital.
Papers were assessed as suitable for inclusion if they met the inclusion criteria detailed above. For the purposes of subgroup and sensitivity analyses, we also recorded other methodological and participant characteristics of included studies.
Categorization of drugs into classes and groups
Drugs associated with admissions were categorized into groups using British National Formulary subchapter headings wherever possible .
Summary statistics for our chosen outcomes were calculated from the selected papers using Microsoft Excel (2000) and are reported as follows:
• The median (range) percentage of all hospital admissions (as reported by study authors) which were drug related and preventable.
• The frequency of drug causes of admissions, reported as the proportion of all drug causes (i.e. greater than the number of admissions, as more than one drug can contribute to a single admission)
• The median percentage (range) of all hospital admissions attributed to an underlying cause (as reported by the study authors). Underlying causes included: prescribing problems (admissions which could have been avoided by prescribing an alternative drug or dose of drug), monitoring problems (admissions which could have been avoided by closer monitoring for adverse effects of medication) and adherence problems (admissions which could have been avoided if patients had taken the drugs according to the prescribed directions).
Description of studies
We identified 122 potentially relevant studies, of which 17 satisfied our inclusion criteria. The main reasons for excluding studies are summarized in the QUOROM flow diagram (see Figure 1). A brief description of the studies included in the review is presented in Table 1. Hallas et al. conducted a series of studies covering a range of hospital wards (general medical, cardiac, older people, gastrointestinal and respiratory) [7–11]. Details of the drugs associated with preventable hospital admissions are published in five papers [7–11], whilst a sixth paper summarized the percentage of preventable drug-related admissions for all the units studied . A seventh paper by Hallas et al. reported the results of a survey of admissions following an intervention which had been developed as a result of the earlier work .
Table 1. Details of studies included in the review
Age of patients
Type of admission
Method of assessment of causality and preventability
Prospective nurse review of A&Erecords and follow-upof medical records ofpatients admitted
700-bed public hospital
Adults (mean age 54.5 years)
All admissions via the emergency department on the first weekof each month
Researcher judgement of causality and preventability
October 1994 to Sep-tember 1995
Percentage of admissions that were drug-related and preventable
The search identified 13 papers which met the inclusion criteria. These were conducted between 1983 and 2002. Five studies were conducted in the UK [14–18], two in Denmark [12, 13], two in the USA [19, 20], two in Australia [21, 22], one in Canada  and one in Italy . Four studies included adults aged ≥ 65 years [14, 17, 21, 23], whilst the remaining studies included adults of all ages. Four studies included only admissions caused by adverse drug reactions [16–19], whilst the remaining nine studies included a wider definition of admissions due to under- and overtreatment. Seven studies included admissions due to problems with patient adherence to medication [12, 13, 15, 21–24]. Eleven studies used multiple reviewers to assess causality and preventability [12, 14–23] and 10 studies used guidelines or specific criteria to assign causality and preventability [12–18, 21–23]. A meta-analysis of the data reported was deemed inappropriate due to the heterogeneity between studies.
The median (range) percentage of admissions that were preventable and drug-related is 3.73 (1.36–15.42). The scatter plot in Figure 2 shows the relationship between total number of admissions and percentage of preventable drug-related admissions. Two small studies showed a higher than expected proportion of preventable drug-related admissions [21, 23]. These studies included admissions due to problems with patient adherence and, in contrast to the other studies, focused on patients aged ≥ 65 years rather than adults of all ages.
Drugs associated with preventable hospital admissions
The search identified 11 papers which met the inclusion criteria [7, 9–11, 13, 15, 16, 18–20, 22]. The studies were conducted between 1983 and 2001 and included adults of all ages. Five studies were conducted in Denmark [7, 9–11, 13], three in the UK [15, 16, 18], two in the USA [19, 20] and one in Australia . The five papers from Denmark [7, 9–11, 13] reported the results of two studies, four papers reported the detailed results for four units [7, 9–11].
Three studies included admissions caused by adverse drug reactions only [16, 18, 20], whilst the remaining studies reported adverse drug reactions, over- and undertreatment and patient adherence problems. To take account of this, the drugs causing admissions have been broken down into three groups: admissions caused by adverse drug reactions and overtreatment; admissions caused by undertreatment; and admissions caused by problems with patient adherence.
The drug groups most frequently associated with all types of preventable drug-related admissions were antiplatelets, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants (see Table 2). When preventable drug-related admissions were broken down by type of underlying problem, adverse drug reactions and overtreatment were most commonly associated with antiplatelets, diuretics and NSAIDs, undertreatment problems with antiepileptics and patient adherence problems with diuretics, drugs used in diabetes and antiepileptics (see Table 2).
Table 2. Drug groups most commonly associated with preventable drug-related admissions relating to adverse drug reactions and overtreatment, undertreatment and problems with patient adherence
All preventable drug-related admissions, no. (%) (n = 1406)
Adverse drug reactions and overtreatment no. (%) (n = 1263)
Patient adherence problems no. (%) (n = 98)
Undertreatment no. (%) (n = 45)
Inhaled and oral bronchodilators and corticosteroids and other antiasthmatic drugs.
Antiplatelets (including aspirin when used as an antiplatelet
Nonsteroidal anti-inflammatory drugs
Drugs affecting the renin–angiotensin system (e.g. angiotensin converting enzyme inhibitors)
Underlying causes of preventable drug-related admissions
The search identified five papers which met the inclusion criteria [12, 15, 19, 22, 23]. The studies were conducted in the USA , Canada , Australia , Denmark  and the UK  between 1983 and 2001. One study included only adults aged ≥ 65 years , whilst the remaining studies included adults of all ages. The underlying causes reported in the papers were prescribing problems (assumed to be a problem if admissions were described as preventable adverse drug reactions and not attributed to monitoring problems), monitoring problems and problems with patient adherence. Other categories were reported in some papers (drug interactions, for example) but could not be applied to all the publications.
Prescribing problems and problems with patient adherence to medication were the most common underlying causes of preventable drug-related admissions [median (range) 30.6% (11.1–41.8) and 33.3% (20.9–41.7), respectively]. Monitoring problems were responsible for a median (range) of 22.2% (0–31.3) preventable drug-related admissions (see Table 3).
Table 3. Numbers (percentage) of preventable drug-related admissions associated with prescribing problems, monitoring problems and patient adherence problems
Number (%) of admissions attributed to different underlying causes
We found that four drug groups accounted for > 50% of preventable drug-related hospital admissions and 12 drug groups accounted for 80% of these admissions. Around one-third of drug-related admissions were associated with prescribing problems, one-third with patient adherence problems and nearly a quarter with inadequate monitoring of medication.
The median of 3.7% of admissions found to be drug related and preventable in our review is slightly lower than that of a previous review  because of the inclusion of two recent large UK studies. To our knowledge, only one other review has attempted to detail the drugs most commonly causing patient injury . This review, however, concentrated on adverse drug reactions causing, and occurring during, hospital admission and did not consider whether the admissions were preventable.
We have focused on studies that used prospective medical record review to identify potential drug-related admissions. It is widely accepted that this is the most comprehensive approach to identifying drug-related hospital admissions  compared with other methods, such as computer alerts  and spontaneous reporting . In addition, the studies included in this review have used either multiple reviewers and/or criteria to assign causality and preventability. The included studies were conducted over a period of 18 years in several different developed countries, mostly in the western hemisphere. Therefore, the results of this study may not be applicable in all countries. Some of the studies used different definitions of causality and preventability and therefore may not be directly comparable. For example, some studies have included admissions considered to be possibly related to drugs and possibly preventable in their assessments of the prevalence of preventable drug-related admissions. In order to avoid falsely inflating the prevalence of preventable drug-related admissions we have, wherever possible, excluded these admissions from the estimates reported in our systematic review.
We have focused on medical admissions to hospital from the general population and have included studies with a broad scope of admission types by excluding studies conducted only on specialist units. However, it is possible that the presence of specialist units in some hospitals may have affected the types of admissions seen.
In all of the cases judged to be preventable in the reviewed studies, the innate toxicity of the drug (or failure to prescribe a drug or sufficient dose) was avoidable in some way. The four drug groups most often causing preventable admissions are commonly used in England . Diuretics account for 5.3% of all primary care prescriptions in England, antiplatelets for 4.0%, NSAIDs for 3.0% and oral anticoagulants for 0.8%. These drug groups have a high innate toxicity, with both diuretics and oral anticoagulants requiring close monitoring for their safe use. In addition, all four drug groups are often used in elderly patients who are more susceptible to adverse effects. The ideal solution to this problem would be to have safer drugs, although no drug is ever likely to be completely without risk. In addition, new drugs take many years to reach the market. In the meantime, there are a number of strategies which can be implemented to help reduce the number of preventable drug-related hospital admissions.
NSAIDs are known to increase the risk of gastrointestinal bleeding and renal dysfunction [29, 30]. Co-prescribing a proton pump inhibitor could reduce the risk of gastrointestinal bleeding (and hospital admission) associated with NSAIDs by between 64% (as secondary prophylaxis) and 78% (as primary prophylaxis) . Other options include using alternative analgesia or prescribing the lowest possible dose of NSAIDs.
Low-dose aspirin also increases the risk of gastrointestinal bleeding . Secondary prophylaxis with Helicobacter pylori eradication, where necessary, and proton pump inhibitors offers a ninefold reduction in the risk of gastric ulcer bleeding .
Close monitoring of patients taking potent diuretics could reduce the number of patients admitted with dehydration and/or renal failure. A nurse-led intervention, which included more frequent monitoring of heart failure patients, reduced hospital admissions due to heart failure by 60% and almost halved the number of days spent in hospital .
Ensuring adequate monitoring of patients on oral anticoagulants and avoiding coprescription of drugs which increase the risk of bleeding could reduce the number of patients admitted with bleeding events . More effective computer alerts may help to avoid the coprescription of interacting drugs and to alert to the need for increased monitoring .
The strategies detailed above concentrate mostly on avoiding adverse drug reactions, but it is also important to remember that preventable patient injury can be caused by undertreatment. Undertreatment can result from prescribing too low a dose, or patients taking less than the prescribed dose of medication. Prescribers should ensure that patients are treated with the minimum effective dose of drug, but not less, especially when prescribing drugs with a narrow therapeutic range, e.g. antiepileptics or digoxin. In addition, it is important to ensure that patients are given adequate information to enable them to take their medication effectively and safely. However, not all cases associated with adherence problems will be avoidable.
While there are a number of studies that suggest ways in which preventable drug-related injuries could be avoided [30–32, 34], it would be helpful to quantify potential benefits and risks using health economic evaluations and, where necessary, further primary research. For example, a health economic evaluation of combining gastro-prophylaxis with low-dose aspirin would help to clarify the patient groups for which prophylaxis might be justified. In addition, there needs to be greater attention to the evidence base which underpins drug monitoring .
Also, despite the large number of studies of preventable drug-related admissions, further studies are needed to provide more information on the underlying causes of these admissions. This may help in the development of interventions aimed at improving the safety of prescribing and drug monitoring, and improving adherence to medication.
Antiplatelets, diuretics, NSAIDs and anticoagulants account for more than half of the drug groups associated with preventable drug-related admissions to hospital. Concentrating interventions on these four drug groups could appreciably reduce the number of preventable drug-related admissions to hospital.
This systematic review was undertaken with NHS Research & Development funding.